" class="no-js "lang="en-US"> INOVIO - Medtech Alert
Friday, September 12, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
INOVIO | Pharmtech Focus

INOVIO

About INOVIO

INOVIO

INOVIO Pharmaceuticals, Inc. (INOVIO) is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure and protect people from infectious diseases, cancer and HPV-associated diseases. ​ INOVIO’s DNA medicines platform and proprietary smart device can target virtually any DNA sequence. With 15 clinical programs currently in development, INOVIO has the potential to save and protect lives worldwide and power a new decade of DNA medicines. ​

Related Story

Drug Development

 INOVIO Announces Orphan Drug Designation for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis | MTA

INOVIO Announces Orphan Drug Designation for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis

May 24 2023

INOVIO, a biotechnology company focused on developing and commercializing DNA medicines to help treat and […]

Appointments

 INOVIO Appoints Dr. Michael Sumner

INOVIO Appoints Dr. Michael Sumner, MB BS, MBA as Chief Medical Officer

June 28 2022

INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect […]

Appointments

 INOVIO Announces the Appointment of Jacqueline Shea

INOVIO Announces the Appointment of Jacqueline Shea, Ph.D., as Chief Executive Officer

May 11 2022

INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect […]